Andy Porter - 27 Jan 2022 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role: Chief Administrative Officer
Signature: /s/ Brian Adams, as Attorney-in-Fact
Issuer symbol: RLAY
Transactions as of: 27 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 31 Jan 2022, 16:28:46 UTC
Previous filing: 27 Dec 2021
Next filing: 31 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RLAY	Common Stock	Award	$0	+24,170	+104%	$0.000000	47,317	27 Jan 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RLAY	Stock Option (Right to Buy)	Award	$0	+48,340		$0.000000	48,340	27 Jan 2022	Common Stock	48,340	$20.38	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. The RSUs shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date.
F2	Includes 35,545 shares underlying RSUs.
F3	The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date.